Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
Both have been FDA cleared for their safety and effectiveness
The top dose produced 20.9% average weight loss over 72 weeks and 20.2% in a direct comparison with semaglutides 13.7%. Its second receptor, GIP, separates tirzepatide from approved single-receptor GLP-1 drugs and helps explain the larger population-level weight loss. That 20.9% came from participants averaging about 105 kg at a BMI of 38, most of whom were sedentary
In REDEFINE 1, GI events were reported in 79.6% of CagriSema participants versus 39.9% on placebo, including nausea (55%), constipation (30.7%), and vomiting (26.1%)
Maintain aseptic handling to preserve compound integrity
US$ 27.16
US$ 20.17
US$ 28.04
US$ 25.10
US$ 23.58
